<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904045</url>
  </required_header>
  <id_info>
    <org_study_id>PEL-1235_REN-0176-I</org_study_id>
    <nct_id>NCT01904045</nct_id>
  </id_info>
  <brief_title>PEL-1235_REN-0176-I (Pelicon)</brief_title>
  <acronym>Pelicon</acronym>
  <official_title>A Multicentre, Prospective, Non-Interventional Study to Assess the Intra-patient Variability of Tacrolimus Once and Twice Daily After Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      Aim of this study is to investigate whether in patients following kidney transplantation (&gt;6
      months after transplantation), the intra-patient variability of levels of tacrolimus is
      comparable after administration of tacrolimus twice daily (Prograf) to tacrolimus once daily
      (Advagraf), with each regimen for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intrapatient variability of tacrolimus through level</measure>
    <time_frame>pre-dose, 1 h post dose and 3 h post dose for 3 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Immunosuppression After Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tacrolimus Advagraf</intervention_name>
    <description>intake of Advagraf once daily for 3 months</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tacrolimus Prograf</intervention_name>
    <description>intake of Prograf twice daily for 3 months</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatient clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed written informed consent

          -  male or female patient ≥ 18years of age

          -  Patient has received a kidney transplantation at least 6 months prior to inclusion
             into the study

          -  No acute rejection episodes for at least 3 months

          -  PRG through level and dosing stable for at least 1 month

          -  Patient is capable of understanding the purpose and risks of the study, has been fully
             informed and has given written informed consent to participate in the study

        Exclusion Criteria:

          -  Acute rejection episodes within the last 3 months prior to study entry

          -  Unstable PRG trough level or dose change in the month before study entry

          -  History of noncompliance to medical regimens

          -  Patients unwilling to or unable to comply with the protocol

          -  Treatment with another investigational product during this study or during the last 30
             days prior to study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Department of Nephrology</name>
      <address>
        <city>Munic</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

